Akebia Therapeutics (AKBA) Cash & Equivalents Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Cash & Equivalents Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | -4.65% |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 13.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.28% |
| Mar 31, 2026 | 43.39% |
| Dec 31, 2025 | 256.36% |
| Sep 30, 2025 | 389.54% |
| Jun 30, 2025 | 247.62% |
| Mar 31, 2025 | 170.00% |
| Dec 31, 2024 | 20.84% |
| Sep 30, 2024 | -26.93% |
| Jun 30, 2024 | -26.27% |
| Mar 31, 2024 | -26.32% |
| Dec 31, 2023 | -52.55% |
| Sep 30, 2023 | -67.86% |
| Jun 30, 2023 | -62.77% |
| Mar 31, 2023 | -67.35% |
| Dec 31, 2022 | -39.61% |
| Sep 30, 2022 | -30.14% |
| Jun 30, 2022 | -41.74% |
| Mar 31, 2022 | -30.92% |
| Dec 31, 2021 | -34.50% |
| Sep 30, 2021 | 22.40% |